期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

厄洛替尼在晚期非小细胞肺癌二线和三线治疗疗效比较 被引量：1

Comparison of the therapeutic efficacy of erlotinib as second line and third line therapy for patients with advanced non-small cell lung cancer
暂未订购
导出
摘要 目的比较厄洛替尼在晚期非小细胞肺癌(NSCLC)二线和三线治疗的疗效差异。方法回顾性分析145例ⅢB期和Ⅳ期接受二线或三线厄洛替尼治疗的NSCLC患者,其中84例患者接受厄洛替尼二线治疗,61例患者接受厄洛替尼三线治疗。应用Kaplan-Meier法进行生存分析。结果厄洛替尼二三线治疗客观缓解率(ORR)分别为15.5%和13.1%(P=0.690),疾病控制率(DCR)分别为61.9%和60.7%(P=0.879),中位无进展生存期(PFS)分别为4.000个月和3.330个月(P=0.334),中位总生存期(OS)分别为21.770个月和25.830个月(P=0.461)。两组不良反应近似。结论厄洛替尼用于晚期NSCLC二线治疗或三线治疗,两者疗效相当。大部分患者能够耐受其不良反应。 Objective To compare the therapeutic efficacy of erlotinib as second line and third line therapy for patients with advanced non-small cell lung caneer （NSCLC）. Methods We retrospectively reviewed 145 cases advanced NSCLC patients in our hospital. 84 cases were given erlotinib as second line therapy and 61 cases were given erlotinib as third line therapy.Survival analysis was evaluated by using Kaplan-Meier method. Results The erlotinib as second-line therapy group was similar to the third-line therapy group in objective response rate （ORR）（15.5% vs 13.1% ,P = 0.690）,the disease control rate （DCR）（61.9% vs 60.7% ,P = 0.879）,the median progression free survival （PFS）（4.000 months vs 3.330 months,P = 0.334）,and the median overall survival （OS）（21.770 months vs 25.830 months,P = 0.46l）. The toxicities in these two groups have not significantly difference. Conclusion There is no significantly difference of response rate or survival benefit between second line and third line therapies with erlotinib in advanced NSCLC. The toxicities could be acceptable in most of the patients.
作者 林宝钗 邵岚 张贝贝 何春晓 郑蕾 洪卫 娄广媛 张沂平
机构地区 浙江中医药大学第二临床医学院 浙江省肿瘤医院化疗中心
出处 《中国现代医生》 2012年第29期52-54,57,共4页 China Modern Doctor
基金 浙江省医药卫生科学研究基金(2010KYA032 2010KYA036) 吴阶平医学基金(320.6750.11059)
关键词 非小细胞肺癌 厄洛替尼 生存分析 Non-small cell lung cancer Erlotinib Survival analysis
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Thatehe RN,Chang A,Parikh P,et al. Gefitinib plus best suppur tive care in previnusly treated patients with refractory advanced non-small- (:ell lung cancer:results from a randomised,plaeebo-controlled,muhi- centre study (lressa Survival Evaluation in Lung Cancer)[J]. I.aneet, 2005,366(9496) : 1527-1537.
  • 2Fisher MD, D'Orazio A. Phase II anti Ⅲ trials:comparison of four ehemntherapy regimens in advanced nnn small-cell lung cancer (ECOG1594)[J]. Clin Lung Cancer,2000,2(1 ):21-22.
  • 3Zhou C,Wu YL, Chen G, el al. Erlotinib versus chemotherapy as first- line treatment for patients with advanced EGFR mutation-positive non- small-cell lung cancer (OPTIMAL, CTONG-0802 ) : a muhicentre, open - label ,randomised ,phase 3 study[J]. Lancet Onco1,20L 1,12 (8) :735 - 742.
  • 4Gridelli C,Ciardiello F,Feld R,et al. International multicenter random- ized phas study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by sec- ond-line E in advanced non-small cell lung cancer (aNSCLC):The TORCH trial[J]. J Clin Oncol,2010,28(15S) :Abstr7508.
  • 5EisenhauerEA ,Therasseb P,Bogaertse J,et al. New respongse evaluation criteria in solid tumours : revised RECIST guideline (version 1.1 ) [J]. Eur J Cancer, 2009,45 (2) : 228-247.
  • 6Trotti A,Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Onco1,2004,22( 1 ):19-22.
  • 7Shepherd FA, Rodrigues PJ,Ciuleanu T,et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 2005,353 (2) : 123-132.
  • 8Ciuleanu T, Stehnakh L, Cicenas S, et al. Efficaey and safety of er- lotinib versus chemotherapy in second-line treatment of patients with advanced,non-small-cell lung cancer with poor prognosis(TITAN):a randomised multicentre,open-label ,phase 3 study[J]. Lancet Oneol, 2012,13(3) : 300-30g.
  • 9Aoki T,Igawa S,Furuya N,et al. Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer[J]. Anticancer Res,2012,32(2) :601-608.
  • 10宋正波,虞永峰,陈智伟,徐云华,李子明,陆舜.晚期非小细胞肺癌吉非替尼二线和三线治疗的疗效比较[J].肿瘤,2011,31(1):53-57. 被引量：5

二级参考文献10

  • 1陆舜,李子明,虞永峰,廖美琳,ZINNER R.吉非替尼治疗复治、晚期非小细胞肺癌的临床分析[J].肿瘤,2006,26(12):1093-1097. 被引量：2
  • 2THATCHER N,CHANG A,PARIKH P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised,placebocontrolled,multicentre study(Iressa Survival Evaluation in Lung Cancer)[J].Lancet,2005,366(9496):1527-1537.
  • 3TS M,WU Y,THONGPRASER S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.
  • 4GRIDELLI C,CIARDIELLO F,FELD R,et al.International multicenter randomized phaseⅢ study of first-line erlotinib(E)followed by second-line cisplatin plus gemcitabine(CG)versus first-line CG followed by second-line E in advanced non-small cell lung cancer(aNSCLC):The TORCH trial[J].J Clin Oncol,2010,28(155):Abstr7508.
  • 5THERASSE P,ARBUCK S G,EISENHAUER E A,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.
  • 6TROTTI A,COLEVAS A D,SETSER A,et al.CTCAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
  • 7KENMOTSU H,GOTO K,NAITO Y,et al.Analysis of optimal timing of gefitinib in sensitive nonsmall cell lung cancer(NSCLC)patients:Should we use gefitinib as first-line chemotherapy?[J].J Clin Oncol,2009,27(15S):Abstr8068.
  • 8ROSELL R,MORAN T,QUERALT C,et al.Screening for epidermal growth factor receptor mutations in lung cancer[J].N Engl J Med,2009,361(10):958-967.
  • 9WU J Y,YU C J,YANG C H,et al.First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer[J].Am J Respir Crit Care Med,2008,178(6):847-853.
  • 10PAUL H,KARI C,ANTOINETTE W,et al.Southwest Oncology Group phase Ⅱ trial(S0341)of erlotinib(OSI-774)in patients with advanced non-small cell lung cancer and a performance status of 2[J].J Thorac Oncol,2008,3(9):1026-1031.

共引文献4

同被引文献19

  • 1Chen WQ,Zheng RS,Zeng HM,et al.2015年中国癌症统计数据[J].中国医学创新,2016,5:6.
  • 2Finkelstein DM,Ettinger DS,Ruckdeschel JC.Longterm survivors in metastatic non-small-cell lung cancer:an Eastern Cooperative Oncology Group Study[J].J Clin Oncol,1986,4:702-709.
  • 3Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
  • 4Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung caner harbouring mutations of the epidermal growth factor receptor(WJTOG 3405):an open label randomized phase 3 trail[J].Lancet Oncol,2010,11(5):121-128.
  • 5Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.
  • 6Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase III trial[J]Lancet,2008,372(9652):1809-1818.
  • 7Ciuleanu T,Stelmakh L,Cicenas S,et al.Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced,non-small-cell lung cancer with poor prognosis(TITAN):a randomized multicentre,open-label,phase 3 study[J].Lancet Oncol,2012,13(3):300-308.
  • 8Shepherd FA,Rodriques Pereira J,et al.Erlotinib in previously treated nonsmall-cell lung cancer[J].N Engl J Med,2005,353(2):123-132.
  • 9Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised,placebo-controlled,multicentre study(Iressa Survival Evaluation in Lung Cancer)[J].Lancet,2005,366(9496):1527-1537.
  • 10Shi Y,Zhang L,Liu X,et a1.Icotinib versus gefitinib in previously treated advanced non-small-cell Lung cancer(ICOGEN):a randomized double-blind phase 3 noninferiority trial[J].Lancet Oncol,2013,14(10):953-961.

引证文献1

中国现代医生
2012年 第29期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部